Association of variants in the ABCB1, CYP2C19 and CYP2C9 genes for Juvenile Myoclonic Epilepsy

被引:0
|
作者
Jara-Prado, Aurelio [1 ]
Guerrero-Camacho, Jorge Luis [1 ]
Angeles-Lopez, Quetzalli Denisse [2 ]
Ochoa-Morales, Adriana [1 ]
de Montellano, David Jose Davila-Ortiz [1 ]
Ramirez-Garcia, Miguel Angel [1 ]
Breda-Yepes, Michelle [3 ]
Duron, Reyna M. [4 ]
Delgado-Escueta, Antonio V. [5 ]
Barrios-Gonzalez, Diego A. [3 ]
Martinez-Juarez, Iris E. [3 ]
机构
[1] Natl Inst Neurol & Neurosurg, Genet Dept, Mexico City, Mexico
[2] UNAM, Fac Estudios Super Cuautitlan, Cuautitlan, Mexico
[3] Natl Inst Neurol & Neurosurg, Epilepsy Clin, Mexico City, Mexico
[4] Univ Tecnol Ctr Amer UNITEC, Tegucigalpa, Honduras
[5] UCLA, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA
关键词
Juvenile Myoclonic Epilepsy; Risk Factor; Genetic Variants; ABCB1; CYPC219; genes; Genes Interaction; BLOOD-BRAIN-BARRIER; BINDING CASSETTE TRANSPORTERS; MDR1; GENE; ULCERATIVE-COLITIS; CYTOCHROMES P450; DRUG-RESISTANCE; P-GLYCOPROTEIN; POLYMORPHISMS; HAPLOTYPES; C3435T;
D O I
10.1007/s10072-023-07124-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Juvenile myoclonic epilepsy (JME) is the most common of the generalized genetic epilepsies, with multiple causal and susceptibility genes; however, its etiopathogenesis is mainly unknown. The toxic effects caused by xenobiotics in cells occur during their metabolic transformation, mainly by enzymes belonging to cytochrome P450. The elimination of these compounds by transporters of the ABC type protects the central nervous system, but their accumulation causes neuronal damage, resulting in neurological diseases. The present study has sought the association between single nucleotide genetic variants of the CYP2C9, CYP2C19, and ABCB1 genes and the development of JME in patients compared to healthy controls. The CC1236 and GG2677 genotypes of ABCB1 in women; allele G 2677, genotypes GG 2677 and CC 3435 in men; the CYP2C19*2A allele, and the CYP2C19*3G/A genotype in both sexes were found to be risk factors for JME. Furthermore, carriers of the TTGGCC genotype combination of the ABCB1 gene (1236/2677/3435) have a 10.5 times higher risk of developing JME than non-carriers. Using the STRING database, we found an interaction between the proteins encoded by these genes and other possible proteins. These findings indicate that the CYP450 system and ABC transporters could interact with other genes in the JME.
引用
收藏
页码:1635 / 1643
页数:9
相关论文
共 50 条
  • [31] Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
    Allabi, AC
    Gala, JL
    Desager, JP
    Heusterspreute, M
    Horsmans, Y
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) : 653 - 657
  • [32] Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene–gene interactions on warfarin therapy
    Koroush Khalighi
    Gang Cheng
    Seyedabbas Mirabbasi
    Bahar Khalighi
    Yin Wu
    Wuqiang Fan
    Journal of Thrombosis and Thrombolysis, 2017, 43 : 124 - 129
  • [33] Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population
    Skadric, Ivan
    Stojkovic, Oliver
    INTERNATIONAL JOURNAL OF LEGAL MEDICINE, 2020, 134 (02) : 433 - 439
  • [34] Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population
    Ivan Skadrić
    Oliver Stojković
    International Journal of Legal Medicine, 2020, 134 : 433 - 439
  • [35] The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
    Rosemary, J.
    Adithan, C.
    CURRENT CLINICAL PHARMACOLOGY, 2007, 2 (01): : 93 - 109
  • [36] Phenazepam's safety pharmacogenetic study results: influence of CYP2C9, CYP3A5, CYP2C19, ABCB1 and CYP3A4/5 isoenzymes' activity
    Ivashchenko, D.
    Ryzhikova, K.
    Sozaeva, Z.
    Grishina, E.
    Zastrozhin, M.
    Bryun, E.
    Sychev, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 : S17 - S18
  • [37] Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia
    Jakovski, K.
    Nestorovska, A. Kapedanovska
    Labacevski, N.
    Dimovski, A. J.
    PHARMAZIE, 2013, 68 (11): : 893 - 898
  • [38] Influence of CYP2C19 and ABCB1 polymorphisms in antiplatelet treatment with clopidogrel
    Davila-Fajardo, C. L.
    Garcia, C.
    Gomez, C.
    Marin, C.
    Cabeza, J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 874 - 874
  • [39] Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
    Guo, YJ
    Zhang, YF
    Wang, Y
    Chen, XY
    Si, DY
    Zhong, DF
    Fawcett, JP
    Zhou, H
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) : 749 - 753
  • [40] Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy
    Song, Cangsang
    Li, Xingde
    Mao, Panpan
    Song, Wenbing
    Liu, Lu
    Zhang, Yang
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (04) : 198 - 201